Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
Objective Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. Methods A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was i...
Saved in:
| Published in: | Obesity (Silver Spring, Md.) Vol. 27; no. 6; pp. 917 - 924 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Blackwell Publishing Ltd
01-06-2019
John Wiley and Sons Inc |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective
Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline.
Methods
A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was identified from six Canadian weight‐management clinics. Post initiation values at 4 and 6 months were compared with baseline values using a paired t test.
Results
The full cohort consisted of 311 participants, with 210 in the ≥ 4‐month persistence group and 167 in the ≥ 6‐month persistence group. Average baseline BMI was 40.7 kg/m2, and weight was 114.8 kg. There was a significant change in body weight 6 and 4 months after initiation of treatment in persistent subjects (≥ 6‐month: −8.0 kg, P < 0.001; ≥ 4‐month: −7.0 kg, P < 0.001) and All Subjects, regardless of persistence (−7.3 kg; P < 0.001). Percentage change in body weight from baseline was −7.1% in the ≥ 6‐month group and −6.3% in the ≥ 4‐month group, and All Subjects lost 6.5% body weight. Of participants in the ≥ 6‐month group, 64.10% and 34.5% lost ≥ 5% and > 10% body weight, respectively.
Conclusions
In a real‐world setting, liraglutide 3.0 mg, when combined with diet and exercise, was associated with clinically meaningful weight loss. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Funding agencies: This study was sponsored by Novo Nordisk A/S. Disclosure: SW is the owner and director of Wharton Medical Clinic (WMC) and is an internal medicine specialist with privileges at Toronto East General Hospital and Hamilton Health Sciences. He has previously received funding in the forms of grants for research from the Canadian Institutes of Health Research and Mitacs. He has also received funding from Novo Nordisk, Eli Lilly and Company, Janssen Pharmaceutica, and AstraZeneca for advisory work. SV is an employee of WMC. RAGC was employed as a research coordinator for WMC. JM and GSP are employees of IQVIA Canada, responsible for study management, analysis, and dissemination. AL and AP are employees of Novo Nordisk Canada Inc. EN and CLH are employees of Novo Nordisk A/S. Author contributions: SW was responsible for the conception and design of the study, for acquisition and interpretation of the data, and for review of the manuscript. SV was responsible for the acquisition of the data. RAGC was responsible for the conception and design of the study, for acquisition and interpretation of the data, and for review of the manuscript. AL was responsible for the interpretation of the data and for review of the manuscript. AP, EN, and CLH were responsible for the conception and design of the study, for interpretation of the data, and for review of the manuscript. JM was responsible for the conception and design of the study, for interpretation of the data, and for the development and review of the manuscript. GSP was responsible for the conception and design of the study, for the analysis and interpretation of the data, and for the development and review of the manuscript. |
| ISSN: | 1930-7381 1930-739X |
| DOI: | 10.1002/oby.22462 |